Multiple Myeloma
The AJMC® Multiple Myeloma compendium is a comprehensive resource for clinical news and expert insights for this cancer.
Latest News
November 7th 2024
Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease progression following standard-of-care therapies that include immunomodulatory agents, proteasome inhibitors, and anti-CD38 antibodies.
EHA 2024: Highlights in Multiple Myeloma
Joseph Mikhael, MD, shares insights surrounding key updates in multiple myeloma management as presented at EHA 2024.
ASH Annual Meeting Coverage: Highlighting the Recent Updates in TKI Use in the Treatment of CML – Insights and Application for Managed Care
Recent Advances in BCMA-Directed Treatment in Multiple Myeloma: Insights and Application for Managed Care
Keeping Pace With New Developments in Multiple Myeloma: Updates and Strategies to Optimize Bispecific Antibodies and CAR T-Cell Therapy
Addressing the Gaps and Clinical Challenges in Chronic Lymphocytic Leukemia: Updates and Strategies for Managed Care
